Demant DEMANT.CO
Demant is a leading Danish group in audiology solutions (hearing aids, cochlear implants, and audiological diagnostics), with an integrated business model combining R&D, manufacturing, and its own network of audiology clinics. Demant shows tight financial health (ND/EBITDA 3.78) but exceptional quality (ROE 23.3%, gross margin 76.25%) and solid growth of 14.8% driven by Oticon Zeal, with reasonable valuation (forward P/E 19.86).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Demant is a leading Danish group in audiology solutions (hearing aids, cochlear implants, and audiological diagnostics), with an integrated business model combining R&D, manufacturing, and its own network of audiology clinics. Demant shows tight financial health (ND/EBITDA 3.78) but exceptional quality (ROE 23.3%, gross margin 76.25%) and solid growth of 14.8% driven by Oticon Zeal, with reasonable valuation (forward P/E 19.86).
Score by category
| Category | Score |
|---|---|
| Financial health | 4.3 |
| Quality / Moat | 7.7 |
| Valuation | 5.2 |
| Growth | 6.6 |
| Dividend | 1.5 |
| Momentum | 7.8 |
| Risk & Context | 7.4 |
OVERALL SCORE: 6.0/10
Context and risks
Moderate governance/regulatory risk in Denmark, with a health system that may pressure hearing aid prices. No material exposure to current macro factors (rates, oil, geopolitics).
News considered in the analysis
- Bernstein unveils top European medtech stock picks to buy for H2 — Recomendación de analista de primer nivel que puede atraer flujos de compra, pero sin información fundamental nueva.
- Demant AS (WILLF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth Fueled by Oticon Zeal ... — Resultados del primer semestre con fuerte crecimiento impulsado por el lanzamiento del producto Oticon Zeal, confirmando la fortaleza del negocio.
- European Companies That May Be Trading Below Their Estimated Value — Listículo genérico sin información específica accionable.
- European Value Stocks Priced Below Estimated Worth In May 2026 — Listículo genérico sin información específica accionable.
- Global Market Value Picks Featuring 3 Stocks With Estimated Discounted Valuations — Listículo genérico sin información específica accionable.
Verdict: Hold; business quality and positive momentum offset leverage, but valuation offers no margin of safety.
Main risk: Financial leverage (ND/EBITDA 3.78) in a rising European rate environment could pressure financial health if growth decelerates.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →